

Kenichi Morikawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4258945/publications.pdf>

Version: 2024-02-01

88
papers

2,356
citations

201385

27
h-index

243296

44
g-index

90
all docs

90
docs citations

90
times ranked

3332
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 232.	1.7	6
2	Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0261760.	1.1	17
3	Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. <i>Scientific Reports</i> , 2022, 12, 1449.	1.6	9
4	The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 508-521.	1.8	1
5	Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon- λ 3 induction in chronic hepatitis B patients. <i>Hepatology Research</i> , 2022, 52, 586-596.	1.8	4
6	Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis. <i>Hepatology Research</i> , 2022, , .	1.8	4
7	Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. <i>Carcinogenesis</i> , 2021, 42, 58-69.	1.3	21
8	Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2021, 56, 168-180.	2.3	29
9	Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass. <i>Journal of Viral Hepatitis</i> , 2021, 28, 755-763.	1.0	6
10	Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0247728.	1.1	3
11	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. <i>Scientific Reports</i> , 2021, 11, 9207.	1.6	8
12	FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2021, 22, 372-380.	1.5	3
13	Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. <i>Nutrients</i> , 2021, 13, 2415.	1.7	8
14	Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. <i>Hepatology Research</i> , 2021, 51, 979-989.	1.8	20
15	Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. <i>Cancers</i> , 2021, 13, 3633.	1.7	10
16	Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. <i>Scientific Reports</i> , 2021, 11, 16616.	1.6	6
17	Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2076-2087.	0.8	4
18	Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. <i>JGH Open</i> , 2020, 4, 54-60.	0.7	36

#	ARTICLE	IF	CITATIONS
19	OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. <i>PLoS ONE</i> , 2020, 15, e0236447.	1.1	7
20	Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19. <i>Hepatology Research</i> , 2020, 50, 1196-1200.	1.8	11
21	Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. <i>JCSM Rapid Communications</i> , 2020, 3, 103-114.	0.6	8
22	Durable response without recurrence to Tolvaptan improves long-term survival. <i>Journal of Gastroenterology</i> , 2020, 55, 1150-1161.	2.3	4
23	Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. <i>Hepatology Research</i> , 2020, 50, 966-977.	1.8	35
24	Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1782-1788.	1.4	22
25	Analysis of the optimal psoas muscle mass index cutoff values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. <i>Hepatology Research</i> , 2020, 50, 715-725.	1.8	28
26	High serum angiotensin II level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. <i>Hepatology Research</i> , 2020, 50, 671-681.	1.8	20
27	Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycomarker for non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2020, 10, 321.	1.6	21
28	Baseline angiotensin II and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. <i>JGH Open</i> , 2020, 4, 880-888.	0.7	13
29	Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 78-86.	2.3	19
30	Correlation between Liver Elasticity by Ultrasound Elastography and Liver Functional Reserve. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 2704-2712.	0.7	9
31	Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. <i>Hepatology Research</i> , 2019, 49, 1294-1304.	1.8	32
32	Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to anti-hepatitis C virus drugs. <i>Hepatology Research</i> , 2019, 49, 1275-1285.	1.8	8
33	Quantifying Protein-Specific N-Glycome Profiles by Focused Protein and Immunoprecipitation Glycomics. <i>Journal of Proteome Research</i> , 2019, 18, 3133-3141.	1.8	12
34	The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. <i>Internal Medicine</i> , 2019, 58, 943-947.	0.3	5
35	Comparative Glycomic Analysis of Sialyl Linkage Isomers by Sialic Acid Linkage-Specific Alkylamidation in Combination with Stable Isotope Labeling of 1,2,3-Linked Sialic Acid Residues. <i>Analytical Chemistry</i> , 2019, 91, 13343-13348.	3.2	12
36	Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. <i>Hepatology Research</i> , 2019, 49, 1207-1217.	1.8	19

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 641-649.	2.3	21
38	Evaluation of clinical utility of PIVKA-II using a chemiluminescent immunoassay. <i>Acta Hepatologica Japonica</i> , 2019, 60, 397-404.	0.0	0
39	Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. <i>Internal Medicine</i> , 2019, 58, 797-802.	0.3	4
40	Enhanced Bâ€cell differentiation driven by advanced cirrhosis resulting in hyperglobulinemia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1667-1676.	1.4	16
41	Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. <i>Hepatology Research</i> , 2018, 48, 529-538.	1.8	15
42	Treatment of hepatitis C in special populations. <i>Journal of Gastroenterology</i> , 2018, 53, 591-605.	2.3	26
43	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. <i>Journal of Gastroenterology</i> , 2018, 53, 119-128.	2.3	49
44	Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. <i>Hepatology Research</i> , 2018, 48, E146-E154.	1.8	1
45	Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. <i>PLoS ONE</i> , 2018, 13, e0209615.	1.1	29
46	Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2749-2756.	2.0	6
47	Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids. <i>Frontiers in Immunology</i> , 2018, 9, 723.	2.2	56
48	Lâ€carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 910-922.	2.0	67
49	Increased serum Câ€reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. <i>Hepatology Research</i> , 2018, 48, E311-E319.	1.8	11
50	Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. <i>Journal of Hepatology</i> , 2017, 67, 1106-1108.	1.8	21
51	Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 270-273.	0.4	11
52	Comparing the risk of hepatitis B virus reactivation between directâ€acting antiviral therapies and interferonâ€based therapies for hepatitis C. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1098-1106.	1.0	35
53	A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. <i>Drugs in R and D</i> , 2017, 17, 381-388.	1.1	12
54	Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. <i>Journal of Gastroenterology</i> , 2017, 52, 1122-1129.	2.3	32

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. <i>Hepatology Research</i> , 2017, 47, 1127-1136.	1.8	31
56	Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. <i>Carcinogenesis</i> , 2017, 38, 1073-1083.	1.3	64
57	Hepatitis B virus X protein impairs interferon signaling via upregulation of suppressor of cytokine signaling 3 and protein phosphatase 2A. <i>Journal of Medical Virology</i> , 2017, 89, 267-275.	2.5	29
58	Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2017, 89, 857-866.	2.5	20
59	Combination of neutrophil-to-lymphocyte ratio and early desferrioxamine carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2017, 47, 533-541.	1.8	13
60	Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection. <i>Annals of Translational Medicine</i> , 2016, 4, 337-337.	0.7	21
61	Viral life cycle of hepatitis B virus: Host factors and druggable targets. <i>Hepatology Research</i> , 2016, 46, 871-877.	1.8	19
62	Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. <i>Hepatology Research</i> , 2016, 46, 1294-1303.	1.8	27
63	Two cases of malignant lymphoma with acute liver failure by the hepatic infiltration. <i>Acta Hepatologica Japonica</i> , 2016, 57, 125-131.	0.0	2
64	Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2016, 51, 733-740.	2.3	103
65	Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 320-327.	0.7	18
66	Increased expression of immunoinhibitory molecules on peripheral blood lymphocytes may suppress disease progression in autoimmune hepatitis. <i>Hepatology Research</i> , 2015, 45, 1152-1154.	1.8	0
67	Intrahepatic artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma. <i>Abdominal Imaging</i> , 2015, 40, 1492-1499.	2.0	31
68	A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 1453-1461.	1.5	22
69	Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN- γ induction by efficient MAVS cleavage. <i>Journal of Hepatology</i> , 2015, 62, 779-784.	1.8	12
70	Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease. <i>Hepatology</i> , 2014, 59, 423-433.	3.6	41
71	Vitamin D Receptor and Jak-STAT Signaling Crosstalk Results in Calcitriol-Mediated Increase of Hepatocellular Response to IFN- γ . <i>Journal of Immunology</i> , 2014, 192, 6037-6044.	0.4	81
72	Neutralizing Antibodies Induced by Cell Culture-Derived Hepatitis C Virus Protect Against Infection in Mice. <i>Gastroenterology</i> , 2013, 145, 447-455.e4.	0.6	70

#	ARTICLE	IF	CITATIONS
73	Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development. <i>PLoS ONE</i> , 2013, 8, e64053.	1.1	59
74	Novel Cell Culture-Adapted Genotype 2a Hepatitis C Virus Infectious Clone. <i>Journal of Virology</i> , 2012, 86, 10805-10820.	1.5	41
75	Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. <i>Hepatology</i> , 2012, 55, 1038-1047.	3.6	36
76	Replication and infectivity of a novel genotype 1b hepatitis C virus clone. <i>Microbiology and Immunology</i> , 2012, 56, 308-317.	0.7	22
77	Production and characterization of HCV particles from serum-free culture. <i>Vaccine</i> , 2011, 29, 4821-4828.	1.7	17
78	Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2009, 81, 619-627.	2.5	39
79	Magnitude of CD8 ⁺ T cell responses against hepatitis C virus and severity of hepatitis do not necessarily determine outcomes in acute hepatitis C virus infection. <i>Hepatology Research</i> , 2009, 39, 256-265.	1.8	5
80	Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins. <i>Biochemical and Biophysical Research Communications</i> , 2008, 371, 446-450.	1.0	24
81	Characterization of infectious hepatitis C virus from liver-derived cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2008, 377, 747-751.	1.0	9
82	Critical Role of Virion-Associated Cholesterol and Sphingolipid in Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2008, 82, 5715-5724.	1.5	186
83	The NS3 Helicase and NS5B-to-3'X Regions Are Important for Efficient Hepatitis C Virus Strain JFH-1 Replication in Huh7 Cells. <i>Journal of Virology</i> , 2007, 81, 8030-8040.	1.5	59
84	CD81 Expression Is Important for the Permissiveness of Huh7 Cell Clones for Heterogeneous Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2007, 81, 5036-5045.	1.5	112
85	An infectious and selectable full-length replicon system with hepatitis C virus JFH-1 strain. <i>Hepatology Research</i> , 2007, 37, 433-443.	1.8	22
86	The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. <i>Journal of Medical Virology</i> , 2007, 79, 714-723.	2.5	60
87	Cell culture and infection system for hepatitis C virus. <i>Nature Protocols</i> , 2006, 1, 2334-2339.	5.5	166
88	Translational enhancement of HCV RNA genotype 1b by 5'-untranslated and envelope 2 protein-coding sequences. <i>Virology</i> , 2006, 345, 404-415.	1.1	3